PL1942933T3 - Szczepionki przeciw grypie psów - Google Patents

Szczepionki przeciw grypie psów

Info

Publication number
PL1942933T3
PL1942933T3 PL06789953T PL06789953T PL1942933T3 PL 1942933 T3 PL1942933 T3 PL 1942933T3 PL 06789953 T PL06789953 T PL 06789953T PL 06789953 T PL06789953 T PL 06789953T PL 1942933 T3 PL1942933 T3 PL 1942933T3
Authority
PL
Poland
Prior art keywords
influenza vaccines
canine influenza
canine
vaccines
influenza
Prior art date
Application number
PL06789953T
Other languages
English (en)
Inventor
Jules Maarten Minke
Kemal Karaca
Jiansheng Yao
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/211,983 external-priority patent/US7384642B2/en
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of PL1942933T3 publication Critical patent/PL1942933T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL06789953T 2005-08-25 2006-08-23 Szczepionki przeciw grypie psów PL1942933T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/211,983 US7384642B2 (en) 2005-08-25 2005-08-25 Canine influenza vaccines
US11/264,622 US7425336B2 (en) 2005-08-25 2005-11-01 Canine influenza vaccines
EP06789953A EP1942933B1 (en) 2005-08-25 2006-08-23 Canine influenza vaccines
PCT/US2006/032914 WO2007024947A2 (en) 2005-08-25 2006-08-23 Canine influenza vaccines

Publications (1)

Publication Number Publication Date
PL1942933T3 true PL1942933T3 (pl) 2013-03-29

Family

ID=37772325

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06789953T PL1942933T3 (pl) 2005-08-25 2006-08-23 Szczepionki przeciw grypie psów

Country Status (11)

Country Link
US (1) US7425336B2 (pl)
EP (1) EP1942933B1 (pl)
JP (1) JP2009506050A (pl)
CA (1) CA2620074C (pl)
CY (1) CY1113540T1 (pl)
DK (1) DK1942933T3 (pl)
ES (1) ES2397707T3 (pl)
PL (1) PL1942933T3 (pl)
PT (1) PT1942933E (pl)
SI (1) SI1942933T1 (pl)
WO (1) WO2007024947A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US20080241184A1 (en) * 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
NZ566490A (en) * 2005-10-07 2011-06-30 Pfizer Prod Inc Live attenuated or killed H3N8 influenza vaccines and methods to treat canine influenza
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ES2377884T3 (es) * 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
PL2368572T3 (pl) * 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
AU2010232180B2 (en) * 2009-03-31 2016-09-22 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
WO2011094693A1 (en) * 2010-02-01 2011-08-04 Mount Sinai School Of Medicine Interferon-inducing compounds and uses thereof
BR112013023354B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção
CA2995382A1 (en) 2015-08-20 2017-02-23 University Of Rochester Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
JP2019520338A (ja) 2016-06-03 2019-07-18 ユニバーシティ オブ ロチェスター ウマインフルエンザウイルス弱毒生ワクチン
LT3471760T (lt) 2016-06-17 2025-02-25 Boehringer Ingelheim Vetmedica Gmbh Nauji imunogeniniai preparatai, apimantys linijinių arba šakotų poliakrilo rūgšties polimerų adjuvantus
MX2020008927A (es) 2018-02-27 2021-01-08 Univ Rochester Vacuna contra la influenza atenuada viva multivalente para la prevencion y el control del virus de la influenza equina (eiv) en caballos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5756430A (en) * 1980-09-19 1982-04-05 Biseibutsu Kagaku Kenkyusho:Kk Live virus vaccine for canine parainfluenza
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
EP2489739B1 (en) * 2005-04-21 2019-11-20 University of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines

Also Published As

Publication number Publication date
US7425336B2 (en) 2008-09-16
CA2620074A1 (en) 2007-03-01
CA2620074C (en) 2014-07-15
DK1942933T3 (da) 2013-01-14
PT1942933E (pt) 2013-01-24
US20070048821A1 (en) 2007-03-01
CY1113540T1 (el) 2016-06-22
SI1942933T1 (sl) 2013-02-28
WO2007024947A3 (en) 2007-05-31
WO2007024947A2 (en) 2007-03-01
ES2397707T3 (es) 2013-03-08
EP1942933B1 (en) 2012-10-17
JP2009506050A (ja) 2009-02-12
EP1942933A2 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
IL196024A0 (en) Influenza vaccine
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
SI2185191T1 (sl) Cepiva proti influenci z majhnimi dodatki
SI2091560T1 (sl) Cepiva proti ptičji gripi za mačke
GB0513421D0 (en) Vaccines
EP1998814A4 (en) NEW VACCINES AGAINST INFLUENZA M2
WO2007051036A8 (en) Influenza combinatorial antigen vaccine
PT2043682E (pt) Vacina da influenza
PT1942933E (pt) Vacinas contra a gripe canina
IL198897A0 (en) Canine leishmania vaccine
GB0524409D0 (en) Vaccines
ZA200709207B (en) Vaccine
GB0810662D0 (en) Vaccine
GB0524408D0 (en) Vaccines
GB0515135D0 (en) Vaccine
GB0516944D0 (en) Vaccine
ZA200900062B (en) Influenza vaccine
GB0511203D0 (en) Vaccines
IL191977A0 (en) Improved influenza vaccine
GB0526412D0 (en) Vaccine
GB0623218D0 (en) Influenza vaccine
GB0623865D0 (en) Influenza vaccine
GB0625453D0 (en) Influenza vaccine
GB0619090D0 (en) Influenza vaccine